Clinical Trials Logo

Filter by:
NCT ID: NCT03448913 Completed - Clinical trials for Chronic Pain Post-Procedural

Block REducing Pain After Surgery Trial

BREAST
Start date: February 1, 2018
Phase:
Study type: Observational

This observational study evaluates difference in chronic pain after six months from surgery between patients who received PECS block and general anesthesia versus general anesthesia alone.

NCT ID: NCT03448692 Terminated - Clinical trials for Focal Segmental Glomerulosclerosis (FSGS)

A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

PODO
Start date: October 15, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusions in adult subjects with FSGS.

NCT ID: NCT03448666 Recruiting - Malignant Melanoma Clinical Trials

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2 multicenter, open label, non-randomized, interventional study enrolling 53 patients.The objectives and purposes of the clinical study described herein are to determine if concomitant Pembrolizumab (Keytruda) and ECT treatments are safe and able to improve local and systemic response rates.ECT will be performed with the CLINIPORATOR and a single IV dose of Bleomycin

NCT ID: NCT03448419 Completed - Heart Failure Clinical Trials

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms

Start date: March 20, 2018
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test in patients with chronic HF with reduced ejection fraction (LVEF ≤ 40%) Secondary objectives are to assess Patient-Reported Outcome (PRO)

NCT ID: NCT03448406 Completed - Heart Failure Clinical Trials

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

Start date: March 20, 2018
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test (6MWT) in patients with chronic heart failure (CHF) with preserved ejection fraction (LVEF > 40%). Secondary objectives are to assess Patient-Reported Outcome (PRO)

NCT ID: NCT03448341 Completed - Clinical trials for Cancer of Nasopharynx

Dysphagia Assessment After Swallowing Sparing RadioTherapy

DASRT
Start date: July 16, 2016
Phase:
Study type: Observational

To prospectively assess post-radiation late dysphagia by using MDADI questionnaire (deglutition-related quality of life) and objective instrumental assessment by means of Fiberoptic Endoscopic Evaluation of Swallowing (FEES) and Videofluoroscopy (VFS) in patients affected by nasopharynx and oropharynx cancers candidates to radiochemotherapy. Radiotherapy is delivered by using Intensity and Modulated Technique (IMRT) with a planning dose optimization to the swallowing related structures (SWOARs-sparing IMRT). The primary aim is to assess the variations of MDADI, FEES and VFS from baseline to 6 and 12 months after treatment. The secondary aim is to correlate clinical and instrumental results as well as radiation dose received by the different swallowing related structures (SWOARs) to the variations of clinical (MDADI) and instrumental (FEES and VFS) scores.

NCT ID: NCT03448198 Completed - Knee Osteoarthritis Clinical Trials

Validation of a New Technique for the Evaluation of the Patello-femoral Joint Kinematics

CINE-FEMORO
Start date: November 16, 2012
Phase: N/A
Study type: Interventional

The objective of this study is to validate a new technique for intraoperative quantification of the patello-femoral joint kinematics in patients undergoing total knee replacement, and for postoperative quantification of implanted knee and general lower limb activity, along with relevant muscle dynamics.

NCT ID: NCT03448042 Active, not recruiting - Solid Tumors Clinical Trials

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Start date: June 6, 2018
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.

NCT ID: NCT03447847 Completed - Healthy Clinical Trials

Effect of Composition and Timing of Ingestion of Fluids on the Urinary Excretion of Lithogenic Substances

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

Interventional crossover study on healthy volunteers aimed at evaluating the effect of the composition and timing of ingestion of different types of water on the urinary excretion of lithogenic substances; the study will also analyze the effect of potassium citrate on urine pH and lithogenic substances

NCT ID: NCT03447769 Terminated - Clinical trials for Non-Small Cell Lung Cancer

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

Canopy-A
Start date: March 16, 2018
Phase: Phase 3
Study type: Interventional

The primary purpose of the study was to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages II -IIIA according to the 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).